Fesoterodine Fumarate Tablet, Extended Release
Product Images NDC 51407-661

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Fesoterodine Fumarate (NDC 51407-661). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Golden State Medical Supply, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

51407-661-30 (51407 661 30)

Label for Fesoterodine Fumarate 4 mg extended-release oral tablets by Golden State Medical Supply, Inc. The label indicates a package of 30 tablets with NDC 51407-661-30. It includes dosing information, storage instructions, and manufacturer details: Dr. Reddy's Laboratories Limited. The label also features a QR code and barcodes.*

FDA Label Image

51407-662-30 (51407 662 30)

Label for Fesoterodine Fumarate 8 mg extended-release tablets, oral use, packaged as 30 tablets. The label includes NDC 51407-662-30 and states Rx Only. Manufacturer is Dr. Reddy's Laboratories Limited, marketed by GSMS, Incorporated. Instructions state to swallow whole and protect from moisture.*

FDA Label Image

Figure1 (Figure1)

A line graph titled 'Change in Number of Micturitions per 24 h (Study 1)' showing mean change from baseline in number of micturitions over 12 weeks. The x-axis represents weeks (0 to 12), and the y-axis shows mean change from baseline (number of micturitions per 24 h) ranging from 0 to -3. The graph compares three groups: Placebo (dotted line, N=279), Fesoterodine fumarate 4 mg (dashed line, N=265), and Fesoterodine fumarate 8 mg (solid line, N=278). Both fesoterodine groups show greater reductions in micturitions compared to placebo over the study period.*

FDA Label Image

Figure2 (Figure2)

Line graph showing the mean change from baseline in urge incontinence episodes per 24 hours over 12 weeks. The graph compares three groups: placebo, Fesoterodine fumarate 4 mg, and Fesoterodine fumarate 8 mg, with the latter two showing greater reduction in episodes compared to placebo over time.*

FDA Label Image

Figure3 (Figure3)

A line graph showing the change in number of micturitions per 24 hours over a 12-week period in Study 2. The y-axis represents the mean change from baseline in number of micturitions per 24 hours, and the x-axis shows time in weeks. Three lines are plotted for placebo, fesoterodine fumarate 4 mg, and fesoterodine fumarate 8 mg groups, demonstrating reductions in micturitions for the active treatment groups compared to placebo over time.*

FDA Label Image

Figure4 (Figure4)

Line graph titled 'Change in Urge Incontinence Episodes per 24 h (Study 2)' depicting mean change from baseline in urge incontinence episodes per 24 hours over 12 weeks. The x-axis represents weeks (0 to 12), and the y-axis shows mean change from baseline ranging from 0.0 to -3.0. Three lines represent Placebo (dotted line), Fesoterodine fumarate 4 mg (dashed line), and Fesoterodine fumarate 8 mg (solid line), illustrating reduction in episodes over time with the 8 mg dose showing the greatest decrease.*

FDA Label Image

Logo1 (Logogsms)

FDA Label Image

Structure (Structure)

Chemical structure of Fesoterodine fumarate, depicting the molecular arrangement of its active ingredient.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.